Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Investigative Ophthalmology & Visual Science|December 30, 2004
Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencingVassiliki Poulaki, Constantine S Mitsiades, Ciaran McMullan, et al.
Transplantation Direct|June 6, 2019
Preformed Donor-specific Antibodies Against HLA Class II and Graft Outcomes in Deceased-donor Kidney TransplantationAudrey Uffing, Luis G Hidalgo, Ciaran McMullan, et al.
Blood|January 18, 2003
Molecular sequelae of histone deacetylase inhibition in human malignant B cellsNicholas Mitsiades, Constantine S Mitsiades, Paul G Richardson, et al.
ESC Heart Failure|October 22, 2024
Projecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trialVeraprapas Kittipibul, Robert J Mentz, Rebecca Young, et al.
Circulation. Heart Failure|August 19, 2021
Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous RegistryJustin Ezekowitz, Robert J Mentz, Cynthia M Westerhout, et al.
European Journal of Heart Failure|July 6, 2022
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trialMichele Senni, Wendimagegn G Alemayehu, David Sim, et al.
Circulation|August 25, 2021
Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA)Justin A Ezekowitz, Yinggan Zheng, Alain Cohen-Solal, et al.
The Journal of Infectious Diseases|May 6, 2025
Safety, Tolerability, and Pharmacokinetics of Once-Monthly Oral Islatravir: a Phase 2a Study in Participants at Low Risk for Acquiring HIV-1Sharon L Hillier, Linda-Gail Bekker, Sharon A Riddler, et al.
Pageof 2